Subscribe to RSS
DOI: 10.1055/a-2095-6367
Intellectual Property in Facial Plastic and Reconstructive Surgery: The Importance and Process of Obtaining Intellectual Property Rights
Abstract
Understanding the purpose and process of obtaining intellectual property rights (IPR) is fundamental to health care innovation. Facial plastic and reconstructive surgeons are natural innovators; however, knowledge deficit in this space may hinder the ability to move ideas from the “bench to bedside.” Here we provide an overview of IPR, outlining the steps necessary to obtain intellectual property protection in an academic setting while highlighting recent U.S. Food and Drug Administration (FDA) approvals pertaining to facial plastic and reconstructive surgery.
Keywords
intellectual property - facial plastic and reconstructive surgery - innovation - FDA - medical devicesPublication History
Accepted Manuscript online:
17 May 2023
Article published online:
23 June 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Smith SW, Sfekas A. How much do physician-entrepreneurs contribute to new medical devices?. Med Care 2013; 51 (05) 461-467
- 2 Bogers M, Afuah A, Bastian B. Users as innovators: a review, critique, and future research directions. J Manage 2010; 36 (04) 857-875
- 3 Heus JJ, de Pauw ES, Mirjam L, Margherita M, Michael R H, Michal H. Importance of intellectual property generated by biomedical research at universities and academic hospitals. J Clin Transl Res 2017; 3 (02) 250-259
- 4 Patino RM. Moving research to patient applications through commercialization: understanding and evaluating the role of intellectual property. J Am Assoc Lab Anim Sci 2010; 49 (02) 147-154
- 5 Nakajima K, Mintz Y, Nickel F, Arezzo A. EAES Technology Committee. The EAES intellectual property awareness survey. Surg Endosc 2022; 36 (05) 3340-3346
- 6 Johns Hopkins Technology Ventures. . The Johns Hopkins University Inventor's Guide. A Brief on Technology Transfer & Commercialization. 2022. Accessed June 2, 2023 at: https://ventures.jhu.edu/wp-content/uploads/2022/07/Inventors-Guide-2022.pdf
- 7 World Intellectual Property Organization. . What is Intellectual Property? Accessed March 12, 2023 at: https://www.wipo.int/about-ip/en/
- 8 Dymond E, Long A, McCarthy A, Drake MJ. Developing a new treatment device: how to get an idea to the marketplace. Neurourol Urodyn 2012; 31 (04) 429-436
- 9 U.S. Patent and Trademark Office. . Types of Patents. Accessed May 2, 2023. https://www.uspto.gov/web/offices/ac/ido/oeip/taf/data/patdesc.htm
- 10 Fini R, Lacetera N, Shane S. Inside or outside the IP system? Business creation in academia. Res Policy 2010; 39 (08) 1060-1069
- 11 Caviggioli F, De Marco A, Montobbio F, Ughetto E. The licensing and selling of inventions by US universities. Technol Forecast Soc Change 2020; 159: 120189
- 12 Hockaday T. University Technology Transfer: What It Is and How to Do It. Baltimore, MD: Johns Hopkins University Press; 2020
- 13 Marcus J. Think universities are making lots of money from inventions? Think again. 2020. Accessed January 17, 2020 at: https://hechingerreport.org/think-universities-are-making-lots-of-money-from-inventions-think-again/
- 14 Stanford Office of Technology Licensing. . Patent. Accessed May, 1 2023 at: https://otl.stanford.edu/patent
- 15 Rameau A, Hong RS, Djalilian H. et al. New medical device and therapeutic approvals in otolaryngology: state of the art review of 2019. OTO Open 2020; 4 (02) 2473974 ×20932506
- 16 Brenner MJ, Shenson JA, Rose AS. et al. New medical device and therapeutic approvals in otolaryngology: state of the art review 2020. OTO Open 2021; 5 (04) 2473974 ×211057035
- 17 Choi AM, Brenner MJ, Gorelik D. et al. New medical device and therapeutic approvals in otolaryngology: state of the art review of 2021. OTO Open 2022; 6 (03) 2473974 ×221126495
- 18 Sanan A, Most SP. A bioabsorbable lateral nasal wall stent for dynamic nasal valve collapse: a review. Facial Plast Surg Clin North Am 2019; 27 (03) 367-371
- 19 Stolovitzky P, Senior B, Ow RA, Mehendale N, Bikhazi N, Sidle DM. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. Int Forum Allergy Rhinol 2019; 9 (08) 850-856
- 20 Sidle DM, Stolovitzky P, Ow RA. et al. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. Laryngoscope 2020; 130 (05) 1132-1137
- 21 Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options. Eye (Lond) 2021; 35 (09) 2468-2481
- 22 Haenisch B, Walstab J, Herberhold S. et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol 2010; 24 (06) 729-739
- 23 Slonim CB, Foster S, Jaros M. et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol 2020; 138 (11) 1168-1175
- 24 U.S. Food and Drug Administration. . UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for topical ophthalmic use. Accessed March 20, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/0212520s000lbl.pdf
- 25 U.S. Food and Drug Administration. . Summary of Safety and Effectiveness Data (SSED): Hemoblast Bellows. 2023. Accessed June 2, 2023 at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170012B.pdf
- 26 U.S. Food and Drug Administration. . Premarket approval (PMA): Hemoblast Bellows. 2023. Accessed June 2, 2023 at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170012S023
- 27 U.S. Food and Drug Administration. . StarPore (Polymer, Ent Synthetic, Porous Polyethylene): 510(k) premarket Notification. 2023. Accessed June 2, 2023 at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200532.pdf
- 28 Kirsner RS, Margolis DJ, Baldursson BT. et al. Fish skin grafts compared to human amnion/chorion membrane allografts: a double-blind, prospective, randomized clinical trial of acute wound healing. Wound Repair Regen 2020; 28 (01) 75-80
- 29 Lullove EJ, Liden B, Winters C, McEneaney P, Raphael A, Lantis Ii JCA. A multicenter, blinded, randomized controlled clinical trial evaluating the effect of omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers. Wounds 2021; 33 (07) 169-177
- 30 Kim TH, Park JH, Jeong HG, Wee SY. The utility of novel fish-skin derived acellular dermal matrix (Kerecis) as a wound dressing material. J Wound Manag Res 2021; 17 (01) 39-47
- 31 U.S. Food and Drug Administration. . Meticuly Patient-Specific Titanium Mesh Implant: 510(k) premarket Notification. 2023. Accessed June 2, 2023 at: https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210099.pdf
- 32 U.S. Food and Drug Administration. . SofWave System: 510(k) premarket Notification. 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211483.pdf
- 33 Fabi SG. Noninvasive skin tightening: focus on new ultrasound techniques. Clin Cosmet Investig Dermatol 2015; 8: 47-52
- 34 Kauvar AN, Geronemus RG, Munavalli GS, Friedman PM, Wang JV, Kilmer SL. Synchronous Ultrasound Parallel Beam Technology Lifts Lax Submental and Neck Skin. Hoboken, NJ: Wiley; 2022. :S20–S20
- 35 Fernandes JR, Samayoa JC, Broelsch GF. et al. Micro-mechanical fractional skin rejuvenation. Plast Reconstr Surg 2013; 131 (02) 216-223
- 36 Russe E, Purschke M, Farinelli WA. et al. Micro-fractional, directional skin tightening: a porcine model. Lasers Surg Med 2016; 48 (03) 264-269
- 37 Pozner JN, Kilmer SL, Geronemus RG, Jack M, Burns JA, Kaminer MS. Cytrellis: a novel microcoring technology for scarless skin removal—summary of three prospective clinical trials. Plast Reconstr Surg Glob Open 2021; 9 (10) e3905
- 38 US Food and Drug Administration. . AI.ME System: 510(k) premarket Notification. 2023. Accessed June 2, 2023 at: https://www.accessdata.fda.gov/cdrh_docs/pdf22/K221011.pdf